COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT05696067

Tatyana Zubkova

Not reported

2023-01-25

Completed

RCT

Randomized

Parallel

Blind label

multi-center

Prevention

inclusion criteria: availability of signed informed consent adult men and women aged 18-60 diagnosed "healthy" according to the data of standard clinical, laboratory and instrumental examination methods, with the absence of clinically significant changes body mass index (bmi): 18.5≤ bmi ≤30 kg/m2 hi antibody titers ≤1:20 to influenza a/h1n1pdm09 and a/h3n2 (only for phase 1) serum antibodies to the sars-cov-2 n-protein not higher than 100 bau/ml the ability and willingness to make entries in the diary of self-observation, as well as to carry out all the visits foreseen in the study for control medical observation negative test for alcohol in exhaled air consent to use effective contraceptive methods throughout their participation in the study values of the complete blood count and biochemical blood analysis (during the screening) within 0.9*reference range lower limit and 1,1 * reference range upper limit negative tests for hiv, hepatitis b, hepatitis c, and syphilis

contact with covid-19 patients within 14 days prior to the start of the clinical study positive rapid test result for sars-cov-2 antigen participation in another clinical study within three months prior to the start of the current study; planning to participate in another study during the current study period. immunization with any other non-study vaccine product, including covid-19 vaccination within four weeks prior to enrollment in the current study, or refusal to postpone such until the end of the four-week period after completion of the current study regular use of nasal irrigation therapy during the last six months prior to enrollment in the current study or episodic use of the above method of treatment in the two weeks prior to the screening history of frequent nosebleeds (>5) during the year prior to the current study clinically significant anatomic pathology or the presence of surgical intervention in the sinus area, paranasal sinuses, or traumatic injuries of the nose within a month before screening symptoms of acute respiratory disease, including fever, or other acute illness at the time of screening or within two weeks prior to screening treatment with immunoglobulins or other blood derived medications in the three months prior to screening or planning such treatment during the period of participation in the current study; donation of blood/plasma (450 ml or more) less than 2 months prior to screening the presence or suspicion of the presence of various immunosuppressive or immunodeficiency conditions or continuous use (the drug was prescribed for more than 14 days without a break) of immunosuppressive drugs, immunomodulators for 6 months before the screening history of bronchial asthma hypersensitivity and the presence of severe allergic reactions, including quincke's edema, anaphylactic shock after the previous administration of any vaccine history of wheezing after previous immunization with live influenza vaccine other adverse events after immunization (fever above 40°c, syncope, non-febrile convulsions, anaphylaxis) when there is a minimal likelihood that they are associated with a previous administration of any vaccine suspicion of hypersensitivity to any component of the study vaccine, including egg protein seasonal (in spring or autumn) increased sensitivity to the effects of natural factors acute or chronic clinically significant lung, cardiovascular, hepatic, endocrine, neurological, or psychiatric disorders, or impaired renal function identified by history, physical examination, or clinical laboratory findings that, in the opinion of the investigator, may influence the outcome of the study history of leukemia or any other malignant diseases of the blood or solid malignant neoplasms of other organs history of thrombocytopenic purpura or bleeding disorders history of convulsions the presence or suspicion of the presence of various immunosuppressive or immunodeficiency conditions, including hiv infection tuberculosis or residual changes after tuberculosis according to the anamnesis and / or available medical documentation chronic alcohol dependence or chronic use of illicit drugs, drug abuse claustrophobia and social phobia according to history and / or available medical records for women of reproductive age - lactation, pregnancy or suspected pregnancy, early postpartum period premenopausal women (last menstrual period <1 year prior to signing informed consent) who are not surgically sterile and women who are of reproductive potential but do not use or plan to use valid birth control throughout the study and do not agree to perform a urine pregnancy test while participating in the study military personnel undergoing military service on conscription persons in custody in pre-trial detention centers and serving sentences in places of deprivation of liberty special diet (eg, vegetarian, vegan, salt-restricted) or lifestyle (night work, extreme physical activity) any condition that, in the opinion of the investigator, may increase the risk to the health of a volunteer participating in the study or affect the results of the study

9

Tatyana Zubkova

18

60

Russia

Healthy volunteers

N/A

200

Level of SARS-CoV-2 antigen specific cytokine producing T-cells;Level of SARS-CoV-2 antigen specific cytokine release in whole blood assay;Level of SARS-CoV-2 antigen specific mucosal and systemic IgA and IgG antibody;Number of participants with local and systemic adverse events (AEs) and serious adverse events (SAEs)

None

Phase 1/Phase 2

[{"arm_notes": "component 1 low dose", "treatment_id": 2685, "treatment_name": "Corfluvec", "treatment_type": "Viral vector (non-replicating)/apc (antigen presenting cell)", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "component 2 low dose", "treatment_id": 2685, "treatment_name": "Corfluvec", "treatment_type": "Viral vector (non-replicating)/apc (antigen presenting cell)", "pharmacological_treatment": "Vaccine"}, {"arm_notes": " component 2 high dose", "treatment_id": 2685, "treatment_name": "Corfluvec", "treatment_type": "Viral vector (non-replicating)/apc (antigen presenting cell)", "pharmacological_treatment": "Vaccine"}, {"arm_notes": " component 1 high dose", "treatment_id": 2685, "treatment_name": "Corfluvec", "treatment_type": "Viral vector (non-replicating)/apc (antigen presenting cell)", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Group 1 low dose", "treatment_id": 2685, "treatment_name": "Corfluvec", "treatment_type": "Viral vector (non-replicating)/apc (antigen presenting cell)", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Group 1 high dose", "treatment_id": 2685, "treatment_name": "Corfluvec", "treatment_type": "Viral vector (non-replicating)/apc (antigen presenting cell)", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Group 1", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}, {"arm_notes": "Group 2a\nHigh dose", "treatment_id": 2685, "treatment_name": "Corfluvec", "treatment_type": "Viral vector (non-replicating)/apc (antigen presenting cell)", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Group 2", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]